XBIT icon

XBiotech

3.88 USD
+0.00
0.00%
At close Jan 10, 4:00 PM EST
After hours
3.88
+0.00
0.00%
1 day
0.00%
5 days
-14.16%
1 month
-41.48%
3 months
-44.33%
6 months
-38.12%
Year to date
-6.95%
1 year
-16.92%
5 years
-78.70%
10 years
-83.31%
 

About: XBiotech Inc is a United States-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.

Employees: 92

0
Funds holding %
of 6,814 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

214% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 7

167% more call options, than puts

Call options by funds: $8K | Put options by funds: $3K

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

58% more capital invested

Capital invested by funds: $23.8M [Q2] → $37.6M (+$13.8M) [Q3]

9% more funds holding

Funds holding: 46 [Q2] → 50 (+4) [Q3]

0.77% more ownership

Funds ownership: 15.18% [Q2] → 15.96% (+0.77%) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for XBIT.

Financial journalist opinion

Based on 26 articles about XBIT published over the past 30 days

Neutral
Accesswire
6 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
NEW YORK, NY / ACCESSWIRE / January 12, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ: XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
Neutral
Accesswire
2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
Neutral
PRNewsWire
4 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
NEW YORK , Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  XBiotech Inc. ("XBiotech" or the "Company") (NASDAQ: XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
Neutral
Accesswire
4 days ago
Shareholders that lost money on XBiotech Inc.(XBIT) should contact Levi & Korsinsky about Securities Fraud Investigation - XBIT
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
Shareholders that lost money on XBiotech Inc.(XBIT) should contact Levi & Korsinsky about Securities Fraud Investigation - XBIT
Neutral
Accesswire
5 days ago
Lost Money on XBiotech Inc.(XBIT)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
Lost Money on XBiotech Inc.(XBIT)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
Neutral
Accesswire
1 week ago
XBIT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of XBiotech Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
XBIT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of XBiotech Inc. Shareholders Who Lost Money
Neutral
Accesswire
1 week ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
NEW YORK, NY / ACCESSWIRE / January 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ: XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
Neutral
Accesswire
1 week ago
XBiotech Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - XBIT
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
XBiotech Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - XBIT
Neutral
Accesswire
1 week ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc.("XBiotech" or the "Company") (NASDAQ:XBIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XBiotech Inc. - XBIT
Neutral
Accesswire
1 week ago
Lost Money on XBiotech Inc. (XBIT)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of XBiotech Inc. ("XBiotech Inc.") (NASDAQ:XBIT) concerning possible violations of federal securities laws. XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint.
Lost Money on XBiotech Inc. (XBIT)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
Charts implemented using Lightweight Charts™